IP Library › Granted Patent US 11,937,809
Granted Patent B2
US 11,937,809 · App. 17/828,261 · Granted Mar 26, 2024

Tissue ingrowth materials and method of using the same

Inventors: Frederick E. Shelton, IV (Hillsboro, OH); Tamara S. V. Widenhouse (Clarksville, OH)
Assignee: Cilag GmbH International
A61B17/068A61B17/072A61B17/07207A61B17/07292A61B2017/00004A61B2017/0046A61B2017/00893A61B2017/00898A61B2017/00938A61B2017/00942A61B2017/07214A61B17/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,937,809
App. No.
17/828,261
Granted
Mar 26, 2024
Kind
B2
Abstract

Implantable materials for use with end effectors like surgical stapling devices, and methods for using the same, are generally provided. In some embodiments, adjunct materials for use with surgical staplers are provided. For example, a kit for stapling tissue is provided that can include a surgical stapler having an end effector. The end effector can have first and second jaws. The kit can include an adjunct material having hydrophobic surface regions and hydrophilic surface regions and the adjunct material can be configured to mate to at least one of the jaws of the end effector. Other implants, devices, and methods for surgical stapling are also provided.

Claims (28)

1. A surgical stapling adjunct material, comprising:

a hybrid adjunct material releasably retained on a cartridge or anvil body configured to compress when a compressive force is applied thereto and to provide a spring back force when compressive force is removed, the hybrid adjunct material having a net ionic charge,

wherein the hybrid adjunct material includes a biologic material layer and a synthetic material layer, and

wherein the synthetic material layer is at least partially permeable and configured to allow one or more components of the biologic layer to pass therethrough.

2. The surgical stapling adjunct material of claim 1 , wherein the hybrid adjunct material is releasably retained on the cartridge or anvil body via a pair of brackets.

3. The surgical stapling adjunct material of claim 1 , wherein the biologic layer comprises a bioabsorbable membrane.

4. The surgical stapling adjunct material of claim 1 , wherein the biologic layer is formed as an extracellular matrix.

5. The surgical stapling adjunct material of claim 1 , wherein the biologic layer comprises a patient-derived material including at least one of platelet enriched plasma, diced tissue fragments, fibrin, and stem cells.

6. The surgical stapling adjunct material of claim 1 , wherein the synthetic layer comprises a lattice structure defining a plurality of openings therethrough, and wherein the one or more components of the biologic material layer are configured to pass through the plurality of openings and contact tissue.

7. The surgical stapling adjunct material of claim 1 , wherein the synthetic layer comprises a polymer mesh.

8. The surgical stapling adjunct material of claim 1 , wherein the synthetic layer comprises at least one of polydioxanone, Polyglycerol sebacate (PGS), PGA (Polyglycolic acid), PCL (Polycaprolactone), PLA or PLLA (Polylactic acid), PHA (polyhydroxyalkanoate), PGCL (poliglecaprone 25), PANACRYL, Polyglactin910, Poly glyconate, PGA/TMC (polyglycolide-trimethylene carbonate), polyhydroxybutyrate (PHB), poly(vinylpyrrolidone) (PVP), poly(vinyl alcohol) (PVA), and a blend of copolymerization of the PGA, PCL, PLA, PDS monomers.

9. The surgical stapling adjunct material of claim 1 , wherein the biologic layer comprises at least one of platelet poor plasma (PPP), platelet rich plasma (PRP), starch, chitosan, alginate, fibrin, thrombin, polysaccharide, cellulose, collagen, bovine collagen, bovine pericardium, gelatin-resorcin-formalin adhesive, oxidized cellulose, mussel-based adhesive, poly (amino acid), agarose, polyetheretherketones, amylose, hyaluronan, hyaluronic acid, whey protein, cellulose gum, starch, gelatin, and silk.

10. The surgical stapling adjunct material of claim 1 , wherein the net ionic charge is configured to attract additional cells in vivo to enhance a healing process.

11. A staple cartridge assembly, comprising:

a cartridge body having a plurality of staples disposed therein; and

a hybrid adjunct material releasably retained on a cartridge or anvil body configured to compress when a compressive force is applied thereto and to provide a spring back force when compressive force is removed, the hybrid adjunct material having a net ionic charge,

wherein the hybrid adjunct material includes a biologic material layer and a synthetic material layer, and

wherein the synthetic material layer is at least partially permeable and configured to allow one or more components of the biologic layer to pass therethrough.

12. The staple cartridge assembly of claim 11 , wherein the hybrid adjunct material is releasably retained on the cartridge or anvil body via a pair of brackets.

13. The staple cartridge assembly of claim 11 , wherein the biologic layer comprises a bioabsorbable membrane.

14. The staple cartridge assembly of claim 11 , wherein the biologic layer is formed as an extracellular matrix.

15. The surgical stapling adjunct material of claim 11 , wherein the biologic layer comprises a patient-derived material including at least one of platelet enriched plasma, diced tissue fragments, fibrin, and stem cells.

16. The staple cartridge assembly of claim 11 , wherein the synthetic layer comprises a lattice structure defining a plurality of openings therethrough, and wherein the one or more components of the biologic material layer are configured to pass through the plurality of openings and contact tissue.

17. The staple cartridge assembly of claim 11 , wherein the synthetic layer comprises a polymer mesh.

18. The staple cartridge assembly of claim 11 , wherein the synthetic layer comprises at least one of polydioxanone, Polyglycerol sebacate (PGS), PGA (Polyglycolic acid), PCL (Polycaprolactone), PLA or PLLA (Polylactic acid), PHA (polyhydroxyalkanoate), PGCL (poliglecaprone 25), PANACRYL, Polyglactin910, Poly glyconate, PGA/TMC (polyglycolide-trimethylene carbonate), polyhydroxybutyrate (PHB), poly(vinylpyrrolidone) (PVP), poly(vinyl alcohol) (PVA), and a blend of copolymerization of the PGA, PCL, PLA, PDS monomers.

19. The staple cartridge assembly of claim 11 , wherein the biologic layer comprises at least one of platelet poor plasma (PPP), platelet rich plasma (PRP), starch, chitosan, alginate, fibrin, thrombin, polysaccharide, cellulose, collagen, bovine collagen, bovine pericardium,

gelatin-resorcin-formalin adhesive, oxidized cellulose, mussel-based adhesive, poly (amino acid), agarose, polyetheretherketones, amylose, hyaluronan, hyaluronic acid, whey protein, cellulose gum, starch, gelatin, and silk.

20. The surgical stapling adjunct material of claim 11 , wherein the net ionic charge is configured to attract additional cells in vivo to enhance a healing process.

Continuity (5)
Continuation 17081222 · Oct 27, 2020
Continuation 16296977 · Mar 8, 2019
Continuation 15645293 · Jul 10, 2017
Continuation 14075459 · Nov 8, 2013
Related Publication 20220287710A1 · Sep 15, 2022
Cited By (1)
US 12,329,377